Clinical Trial Update: Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating second-line therapy for progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extra-pulmonary Neuroendocrine Carcinoma
• Neuroendocrine Carcinoma

Snippet

Sponsor: The Christie NHS Foundation Trust | Conditions: Oncology, Neuroendocrine Carcinoma | Phase 2 | Status: COMPLETED